Redeye provides a short comment on IRLAB’s announcement that MSRD (Otsuka) has issued a USD4m payment to advance IRL757 into a phase Ib study in Parkinson’s patients with apathy. With regulatory preparations now completed and first patient enrollment expected before year-end, the program remains on track.
LÄS MER
